Mycophenolate Mofetil for the Treatment of Cutaneous Lupus Erythematosus With Smoldering Systemic Involvement

Hanjani, N. Michelle; Nousari, Carlos H.

doi:10.1001/archderm.138.12.1616

Cited by 36 publications

(18 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fewer publications evaluate MMF's ability to treat skin manifestations. [49][50][51][52][53][54][55][56][57] One retrospective study reported overall poor results and even worsening of skin flares in one subject. 52 Otherwise, the majority of reported cases are encouraging often with quick response, long-term disease control, or even complete remission.…”

Section: Connective Tissue Disordersmentioning

confidence: 99%

Mycophenolate mofetil in dermatology

Orvis

Wesson

Breza

et al. 2009

Journal of the American Academy of Dermatology

114

106

View full text Add to dashboard Cite

Section: Connective Tissue Disordersmentioning

confidence: 99%

Mycophenolate mofetil in dermatology

Orvis

Wesson

Breza

et al. 2009

Journal of the American Academy of Dermatology

114

106

View full text Add to dashboard Cite

“…61 An improvement of cutaneous lesion was obtained after the introduction of MMF at the dosage of 3 g/day.…”

Section: Skin Manifestationsmentioning

confidence: 96%

Mycophenolate mofetil and systemic lupus erythematosus

Doria

Iaccarino

Arienti

et al. 2006

Lupus

View full text Add to dashboard Cite

Mycophenolate mofetil (MMF) is an immunosuppressive agent which provides protection against acute transplant rejection, in patients who undergo kidney, heart and liver transplantation. Recently MMF has been used in various autoimmune conditions, including systemic lupus erythematosus (SLE). In SLE, MMF has been more extensively used in the treatment of proliferative lupus glomerulonephritis (GLN) and following the success in this field, it has also been used to control extra-renal manifestations. However, in the majority of cases MMF was administered to patients with refractory SLE manifestations and, therefore, no definite conclusion could be drawn from these experiences.In this paper, after a brief description of the mechanisms of action, the pharmacokinetics and metabolism of MMF which are relevant in SLE, and after a short discussion on the utility of performing therapeutic dose monitoring of mycphenolic acid, the experiences with the use of this drug in the different SLE manifestations were summarized and some personal data in patients with GLN were reported. Finally, the hypothetical use of MMF as a preventive strategy against the occurrence of severe manifestations in patients with mild SLE has been put forward and discussed. Lupus (2006) 15, 44-54.

show abstract

“…Another therapy that has been used for recalcitrant CLE is mycophenolate mofetil [43][44][45]. It is a reversible inhibitor of inosine monophosphate dehydrogenase and is used as an immunosuppressant in organ transplant patients.…”

Section: Mycophenolate Mofetilmentioning

confidence: 99%